Major Depressive Disorder Insights and Trends

• Depression is a common mental health disorder characterized by persistent feelings of sadness, hopelessness, and a loss of interest or pleasure in activities once enjoyed. Also known as major depressive disorder (MDD) or clinical depression, it can significantly affect a person's emotions, thoughts, behaviors, and overall functioning, often leading to a range of emotional, cognitive, and physical symptoms that impact daily life.
• The growing prevalence of depression, increasing mental health awareness, and improved psychiatric screening practices are contributing to a rising diagnosed patient pool across the globe.
• \MDD is more prevalent in females (~65%) than males in US in 2025.
• There were more than 10 million females and nearly 7 million males among the gender-specific diagnosed prevalent cases of MDD in EU4 and the UK in 2025.
• According to World Health Organization (2025),  an estimated 5.7% of adults suffer from depression, globally.
• Diagnosis MDD remains largely dependent on subjective clinical assessments and patient-reported symptoms rather than definitive biological tests. The absence of validated biomarkers can lead to delayed diagnosis and misclassification, highlighting the need for more precise and objective diagnostic approaches.

Major Depressive Disorder (MDD) Epidemiology Forecast in the 7MM

• 2025 Prevalent Cases of MDD: ~45 million
• MDD Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Major Depressive Disorder Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the MDD, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Major Depressive Disorder (MDD) Understanding and Diagnosis Algorithm

Major Depressive Disorder (MDD) Overview

MDD is a chronic and debilitating psychiatric disorder characterized by persistent feelings of sadness, loss of interest or pleasure in daily activities, low energy, impaired concentration, sleep disturbances, appetite changes, and feelings of worthlessness or hopelessness. The condition can substantially impair social, occupational, and cognitive functioning and, in severe cases, may lead to suicidal ideation or self-harm. MDD is considered a multifactorial disorder influenced by genetic susceptibility, neurochemical imbalances, psychosocial stressors, inflammation, and alterations in neural circuitry involving serotonergic, dopaminergic, glutamatergic, and stress-response pathways. It represents one of the leading causes of disability worldwide and poses a significant public health and economic burden.

Further details are provided in the report...

Major Depressive Disorder (MDD) Diagnosis

Diagnosis of MDD is primarily based on clinical evaluation and psychiatric assessment using standardized diagnostic criteria such as those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Patients typically present with depressive symptoms lasting for at least two weeks, including depressed mood, diminished interest, fatigue, sleep abnormalities, psychomotor changes, impaired cognition, and suicidal thoughts. Clinicians may utilize validated screening tools such as the Patient Health Questionnaire-9 (PHQ-9), Hamilton Depression Rating Scale (HAM-D), and Montgomery–Åsberg Depression Rating Scale (MADRS) to assess symptom severity and monitor treatment response. Since no definitive laboratory biomarker currently exists for MDD, diagnosis largely relies on symptom evaluation, medical history, and exclusion of other psychiatric or medical conditions.

Further details are provided in the report...

Major Depressive Disorder (MDD) Epidemiology

Key Findings from Major Depressive Disorder (MDD) Epidemiological Analysis and Forecast

• As per DelveInsight analysis, the total diagnosed prevalent cases of MDD in the 7MM were found to be ~45 million cases in 2025, which are expected to increase during the forecast period (2026-2036).
• In 2025, the US accounted for the highest diagnosed prevalent cases of MDD in the 7MM with ~22 million cases.
• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of MDD in 2025, followed by UK, while Spain reported the lowest cases.
• Based on severity, moderate severity cases of MDD were the highest ~40% followed by severe cases and mild cases in the US.

Scope of the Major Depressive Disorder Epidemiology Report

• The report covers a segment of a descriptive overview of MDD, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Major Depressive Disorder Epidemiology Report Insights

Major Depressive Disorder (MDD) Patient Population Forecast

• Report Key Strengths
• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of MDD? What will be the growth opportunities across the 7MM concerning the patient population with MDD?
• What is the historical and forecasted MDD patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.